As the drug development process is becoming increasingly challenging and costly and, all too often, promising candidates fail to become manufacturable and marketable therapies, the industry needs to find new and more innovative ways to extend its product pipelines.  Furthermore, as new therapeutic agents emerge, such as proteins and gene therapy, there is an increasing need for the development of new formulation technologies. The search for new drug delivery systems is now a central issue to address these needs.

Inovapotek experts are specialized on the development of functionalized nanomedicines and their application in the pharmaceutical and biomedical fields. Moreover, they are experienced in using in vitro cell models as a tool to evaluate the transport of drugs and nanoparticles and perform in vitro/in vivo correlations. Particularly, mucosal tissue engineering models for validation of new functionalized nanoparticles for diagnosis and therapy is a relevant field of interest. Past and current research projects have focused on the properties of nanoparticles, modulating their mucoadhesion behavior, ultimately related with passive targeting to gastrointestinal and pulmonary mucosae.

Therefore, besides providing outsourcing services, inovapotek develops R&D projects in collaboration with worldwide scientific and technological institutions, other R&D companies, pharmaceuticals and medical devices industries, being the perfect SME partner for consortium R&D projects.